6. Bakker MF, Jacobs JW, Welsing PM, et al. Are switches from oral to subcutaneous methotrexate or addition of ciclosporin to methotrexate useful steps in a tight control treatment strategy for rheumatoid arthritis? A post hoc analysis of the CAMERA study. Ann Rheum Dis 2010;69:1849Ð52. 7. Verstappen SM, Jacobs JW, van der Veen MJ, et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis 2007;66:1443Ð9. 8. Aletaha D, Smolen JS. The SimpliÞed Disease Activity Index (SDAI) and Clinical Disease Activity Index (CDAI) to monitor patients in standard clinical care. Best Pract Res Clin Rheumatol 2007;21:663Ð75. 9. Prevoo ML, van Ôt Hof MA, Kuper HH, et al. ModiÞed disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44Ð8. 10. Wells G, Becker JC, Teng J, et al. Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis 2009;68:954Ð60. 11. Hart LE, Tugwell P, Buchanan WW, et al. Grading of tenderness as a source of interrater error in the Ritchie articular index. J Rheumatol 1985;12:716Ð7. 12. Thompson PW, Hart LE, Goldsmith CH, et al. Comparison of four articular indices for use in clinical trials in rheumatoid arthritis: patient, order and observer variation. J Rheumatol 1991;18:661Ð5. 13. Uhlig T, Kvien TK, Pincus T. Test-retest reliability of disease activity core set measures and indices in rheumatoid arthritis. Ann Rheum Dis 2009;68:972Ð5. 14. Pincus T. The American College of Rheumatology (ACR) Core Data Set and derivative Òpatient onlyÓ indices to assess rheumatoid arthritis. Clin Exp Rheumatol 2005;23 (5 Suppl 39):S109Ð13. 15. Crowson CS. Rheumatoid arthritis and heart disease: the chicken and the egg? J Intern Med 2010;268:552Ð4. 16. Chambers RE, MacFarlane DG, Whicher JT, et al. Serum amyloid-A protein concentration in rheumatoid arthritis and its role in monitoring disease activity. Ann Rheum Dis 1983;42:665Ð7. 17. Urata Y, Uesato R, Tanaka D, et al. Treating to target matrix metalloproteinase 3 normalisation together with disease activity score below 2.6 yields better effects than each alone in rheumatoid arthritis patients: T-4 Study. Ann Rheum Dis 2011 2012;71:534Ð40. 18. Johansen JS, Stoltenberg M, Hansen M, et al. Serum YKL-40 concentrations in patients with rheumatoid arthritis: relation to disease activity. Rheumatology (Oxford) 1999;38:618Ð26. 19. Mease PJ. The potential roles for novel biomarkers in rheumatoid arthritis assessment. Clin Exp Rheumatol 2011;29:567Ð74. Clinical and epidemiological research 20. Kotzin BL, Falta MT, Crawford F, et al. Use of soluble peptide-DR4 tetramers to detect synovial T cells speciÞc for cartilage antigens in patients with rheumatoid arthritis. Proc Natl Acad Sci USA 2000;97:291Ð6. 21. Ling H, Recklies AD. The chitinase 3-like protein human cartilage glycoprotein 39 inhibits cellular responses to the inßammatory cytokines interleukin-1 and tumour necrosis factor-alpha. Biochem J 2004;380:651Ð9. 22. Ozgonenel L, Cetin E, Tutun S, et al. The relation of serum vascular endothelial growth factor level with disease duration and activity in patients with rheumatoid arthritis. Clin Rheumatol 2010;29:473Ð7. 23. Tchetverikov I, Lard LR, DeGroot J, et al. Matrix metalloproteinases-3, -8, -9 as markers of disease activity and joint damage progression in early rheumatoid arthritis. Ann Rheum Dis 2003;62:1094Ð9. 24. Eastman S, Manning B, Qureshi F, et al. Assay development for precise measurement of disease activity serum biomarkers. Annals of the rheumatic diseases 2010;69:179. 25. Cavet G, Centola, M, Shen Y, et al. Development of a multi-biomarker test for rheumatoid arthritis (RA) disease activity. Annals of the rheumatic diseases 2010;69:148. 26. Verstappen SM, Bakker MF, Heurkens AH, et al. Adverse events and factors associated with toxicity in patients with early rheumatoid arthritis treated with methotrexate tight control therapy: the CAMERA study. Ann Rheum Dis 2010;69:1044Ð8. 27. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classiÞcation of rheumatoid arthritis. Arthritis Rheum 1988;31:315Ð24. 28. Bijlsma JWJ, Oude Heuvel CHB, Zaalberg A. Development and validation of the Dutch questionnaire capacities of daily life (VDF) for patients with rheumatoid arthritis. Rehabil Sci 1990;3:71Ð74. 29. Fleischmann RM, Curtis JR, Hamburger MH, et al. RA population characteristics in InFoRM, a longitudinal observational study. Ann Rheum Dis 2010;69:657. 30. Inoue E, Yamanaka H, Hara M, et al. Comparison of Disease Activity Score (DAS)28- erythrocyte sedimentation rate and DAS28- C-reactive protein threshold values. Ann Rheum Dis 2007;66:407Ð9. 31. Benjamini Y, Hochberg M. Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of the Royal Statistical Society. Series B, Statistical methodology 1995;57:289Ð300. 32. Schipper LG, van Hulst LT, Grol R, et al. Meta-analysis of tight control strategies in rheumatoid arthritis: protocolized treatment has additional value with respect to the clinical outcome. Rheumatology (Oxford) 2010;49:2154Ð64. 33. Abdelmonem A, Clark VA, May S. Computer-Aided Multivariate Analysis, Fourth Edition. Boca Raton, Florida: Chapman and Hall/CRC 2004:1−489. 34. Shen Y, Dirven L, Cavet G, et al. Serum biomarkers predict progressive structural damage in the BeSt study. Arthritis Rheum 2010;62:1496. Ann Rheum Dis 2012;71:1692–1697. doi:10.1136/annrheumdis-2011-200963 annrheumdis-2011-200963.indd 6 1697 8/23/2012 3:34:19 AM